The Data and Safety Monitoring System (DSMS) of UW Carbone Cancer Center (UWCCC) ensures that all clinical research being conducted under the auspices of UWCCC is in compliance with federal requirements and most importantly that human subject safety is always optimized. The DSMS is assisted in its mission of safety and compliance by experienced UWCCC research staff, a Data and Safety Monitoring Committee (DSMC) composed of experienced clinical researchers, and the ongoing use of the Clinical Research Management System (CRMS), OnCore by Forte Research Systems, which allows efficient tracking of protocols and protocol subjects. The DSMC reviews reports on quality assurance (internal audits, quality assurance reviews, response reviews, protocol summary reports, and compliance reviews), protocol deviations/non-compliance, and serious adverse events. The DSMC also provides data review, data abstraction and entry, forms monitoring and final report generation for studies developed and solely monitored by UWCCC. The DSMC is chaired by Anne Traynor, M.D., Associate Professor of Medicine, and co-chaired by KyungMann Kim, Ph.D., Professor of Biostatistics and Medical Informatics, each with over 15 years of clinical trials experience.
The Data and Safety Monitoring System of the UWCCC ensures that all clinical research being conducted under the auspices of the UWCCC is in compliance with federal requirements and most importantly that human subject safety is always optimized.
|Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70|
|Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24|
|Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31|
|Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17|
|Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607|
|Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609|
|Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8|
|LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76|
|Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9|
|Nihal, Minakshi; Wu, Jianqiang; Wood, Gary S (2014) Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys 563:101-7|
Showing the most recent 10 out of 472 publications